Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.

ABSTRACT:

Background

Omalizumab, an anti-IgE monoclonal antibody, is administered by injection once or twice monthly in offices and clinics. It offers a potential alternative intervention for patients with allergic asthma that is not well controlled because of recalcitrant poor adherence to inhaled corticosteroid therapy.

Objective

To assess the effect of omalizumab therapy by measuring airway responsiveness to adenosine, a marker of allergic airway inflammation, and resource use.

Methods

Patients (N = 17) aged 6 to 26 years (mean age, 16.4 years) with poorly controlled persistent allergic asthma, less than 50% adherence to inhaled corticosteroid therapy, a forced expiratory volume in 1 second (FEV1) of 60% predicted or higher, and adenosine provocation concentration that cause

SUBMITTER: Hendeles L 

PROVIDER: S-EPMC4948294 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature